Predicting response and toxicity in patients receiving paclitaxel and Avastin [bevacizumab] for breast cancer: a multicenter genomic, proteomic and pharmacogenomic correlative study.
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2011
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- 21 Apr 2011 Planned end date changed from 1 Dec 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.
- 02 Sep 2009 Actual patient number (11) added as reported by ClinicalTrials.gov.
- 02 Sep 2009 Planned end date changed from 1 Sep 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.